{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18","upperLimit":"64","value":"38"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"The percentage of patients with at least 1 occurrence of grade 3 or higher CTCAE adverse experience will be provided. Ineligible patients or patients who do not receive any protocol therapy are excluded from reporting of adverse events.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients will receive 1 intra-arterial injection (IA) of melphalan every 21- 30 days. Injections may be repeated every 21-30 days (up to a maximum of 3 cycles) assuming the patients meets the criteria to begin the next cycle.","id":"OG000","title":"Melphalan"}],"paramType":"NUMBER","populationDescription":"One patient who did not receive protocol therapy was excluded.","reportingStatus":"POSTED","timeFrame":"Up to 30 days after completion of study treatment","title":"Incidence of Grade 3 or Higher CTCAE Adverse Events Associated With Multiple Doses of IA Chemotherapy","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}